This is part of a series of stories that comprise TheStreet’s Blue Chip Studio, which will illuminate issues related to corporate board performance, activism, dealmakers and personalities revealed by analysis of data generated by BoardEx, a business unit of TheStreet.
BlackRock (BLK), the world’s largest asset manager, said it will be putting pressure on companies to address boardroom diversity as part of a series of initiatives for 2017-2018 that the company’s 30-member Investment Stewardship team will discuss with portfolio companies.
The New York-based firm, with $5.1 trillion under management, said board composition, effectiveness, and accountability remain a top priority, and that it plans to engage companies in a constructive manner.
“More specifically, over the coming year, we will engage companies to better understand their progress on improving gender balance in the boardroom,” the firm said on its website on Monday. “Diverse boards, including but not limited to diversity of expertise, experience, age, race and gender, make better decisions.”
Top Blue Chip Stocks To Own Right Now: Lexaria Bioscience (LXRP)
- [By Matthew Briar]
What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.
Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.
Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.
NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.
Pterostilbene (found in blueberries, by the way) is o
- [By Matthew Briar]
Granted, it’s not always a fully-appreciated distinction. Even though the federal government accurately recognizes that hemp and marijuana are only variants of the same species, Cannabis sativa, the DEAdoesn’t necessarily enforce its drug laws as such. For legitimate medical purposes, the government is perfectly willing to leave the matter alone.
The good news is, governments – federal as well as state – are finally starting to figure out the distinct differences between marijuana and hemp, and that bodes well for a young and hungry startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).
- [By Matthew Briar]
Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).
Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.
It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.
The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp
- [By Bryan Murphy]
When you’ve come up with a technology that increases the digestion of minerals, vitamins, compounds, nutrients, and even medicine, the first thing you want to do is protect that idea so nobody else can commercialize it except you. Well, Lexaria Bioscience Corp (OTCMKTS:LXRP) has figured out how to do the former, and it’s been doing the latter… in spades. First it started by building a wall around its platform in the United States, but as of today’s press release is building a wall internationally as well.
It’s an exciting prospect to be sure. In simplest terms, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.
It’s largely unrecognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes the game, so to speak. How? A proprietary process that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.
The science: Lexaria Bioscience has defined a way to combine cannabinoids with lipids — or fatty acids — at the molecular level. It matters, because the human endocannabinoid system is itself lipid based, making this format the easiest and most effective means of introducing the medicinal and health benefits of hemp and hemp oil.
And the results have been impressive in two different studies
- [By Jim Robertson]
In October, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP) was issuedU.S. Patent No. 9,474,725 Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof and now the company is seeking to expand this patent internationally. This patent protects Lexaria Bioscience Corps intellectual property related to infusion of cannabinoid compounds in edible products and includes a set of claims that describe the Companys method of combining a fatty acid compound with any non-psychoactive cannabinoid for improved bioavailability and taste performance in both food and beverage formats.
- [By Bryan Murphy]
Though they’re not the same thing, anything that’s good for marijuana is good for hemp. That’s why when eight out of nine states that had marijuana on the ballot two Tuesday’s ago approved those measures, things got a lot more compelling for owner of Lexaria Bioscience Corp (OTCMKTS:LXRP).
What’s the difference? Hemp a strains of Cannabis sativa that have been bred specifically for fiber used for clothing, construction, oils and topical ointments, nutritional benefits and a wide array of other purposes that don’t involve getting “high.” Marijuana is a slang term used to describe strains of Cannabis sativa that are bred for the potent resinous glands, or trichomes, that grow on the flowers and some leaves… the strain packed with tetrahydrocannabinol (or THC).
They would be easy to confuse, and commonly are. The potential for confusion, in fact, is the chief reason government agencies have been hesitant to support one and ban the other. With marijuana now legalized for use for one reason or another in more than half the United States though, knowledge and understanding of the difference will soon follow.
Great, but what’s that got to do with Lexaria Bioscience is on the leading edge of the movement of heightened understanding of what hemp is, and what it does.
The medical benefits of the non-psychoactive form of Cannabis sativa are impressive to say the least. Among other benefits, hempseed oil has also shown a positive effect on dermatological diseases and lipid metabolism (the process by which fatty acids are broken down in the body). Hempseed also has high levels of vitamins A, C and E and ?-carotene, and it is rich in minerals like phosphorus, potassium, magnesium, sulfur and calcium. As a food, hempseed oil is nutritious – it contains an excellent balance of polyunsaturated fatty acids – and it reportedly tastes good, too.
Problem: Hemp isn’t effectively absorbed into the body, and as such, it’s difficult to make effec
Top Blue Chip Stocks To Own Right Now: Dow Treasuries(DV)
- [By Peter Graham]
A long term performance chart of Apollo Education Group along with peersITT Educational Services, Inc (NYSE: ESI) and DeVry Education Group Inc (NYSE: DV) reflect the headwinds from the Obama administration:
Top Blue Chip Stocks To Own Right Now: Check Point Software Technologies Ltd.(CHKP)
- [By Jayson Derrick]
It is unclear which company or companies will benefit from this executive order. But that isn’t stopping investors from placing their bets as most cybersecurity stocks were trading higher during Friday’s trading session; at the same time, the Dow Jones Industrial Average and S&P 500 index were trading in the red.
Shares of Barracuda Networks Inc (NYSE: CUDA) were trading higher by 2.98 percent at $21.77. Shares of Check Point Software Technologies Ltd. (NASDAQ: CHKP) were trading higher by 1.21 percent at $107.00. Shares of FireEye Inc (NASDAQ: FEYE) were trading higher by 0.70 percent at $14.55. Shares of Palo Alto Networks Inc (NYSE: PANW) were trading higher by 0.62 percent at $115.86.
- [By WWW.THESTREET.COM]
Turning Around Cybersecurity Through Activism
As competition climbs and spending slows, security has attracted activists. (FEYE) (IMPV) (FTNT) (CHKP) Full story
- [By Harsh Chauhan]
But is it a good idea to buy FireEye based on this one incident, despite its huge losses, or should investors look at Check Point Software Technologies(NASDAQ:CHKP), given its focus on growing its bottom line? Let’s find out.
Top Blue Chip Stocks To Own Right Now: Embraer-Empresa Brasileira de Aeronautica(ERJ)
- [By Lisa Levin]
In trading on Friday, industrials shares fell by 0.12 percent. Meanwhile, top losers in the sector included Stericycle Inc (NASDAQ: SRCL), down 17 percent, and Embraer SA (ADR) (NYSE: ERJ), down 13 percent.
- [By Paul Ausick]
Boeing also confirmed on Thursday that it has discussed a “possible combination” with Brazil’s Embraer S.A. (NYSE: ERJ), a response to the deal Bombardier struck with Airbus in which the European company took control of Bombardier’s C Series program. A deal between Boeing and Embraer is no sure thing, mainly because the Brazilian government holds a controlling interest in Embraer.
Top Blue Chip Stocks To Own Right Now: SPDR S&P Bank ETF (KBE)
- [By ]
Shares of banks have underperformed this year on a narrow net interest margin, the difference between long-term and short-term rates, and continued regulatory costs from post-crisis legislation. The SPDR S&P Bank ETF (NYSE: KBE) has returned just 3.3% this year versus a 15% increase in the broader S&P 500 index.
- [By Ben Levisohn]
The market clearly likes the rate hike today. The S&P 500 has gained 1% to2,388.03 at 3:01 p.m. today. The Financial Select Sector SPDR ETF (XLF) has is little changed at $24.78, while the SPDR S&P Bank ETF (KBE) has dropped 0.7% to $44.59.
- [By Ben Levisohn]
Heck, it might just be easier to buy the lot, especially if you think earnings will be awesome. There’s an ETF for that you know (the SPDR S&P Bank ETF (KBE))?
Top Blue Chip Stocks To Own Right Now: UNIVERSAL INSURANCE HOLDINGS INC(UVE)
- [By Jim Robertson]
Small cap Florida insurance stock Universal Insurance Holdings (NYSE: UVE) has taken a hit with shares downalmost 17%over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 8.51%on Friday when it became clear that it would not be as catastrophic as feared: